dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse

This website has run out of funding so feel free to contribute if you can afford it (see footer)

Author Topic: KemPharm (KMPH) to Initiate Development of Oxymorphone Oral Prodrug KP746  (Read 414 times)

Z

  • Guest
KemPharm, Inc. (NASDAQ: [color=rgb(59, 101, 146) !important]KMPH[/color]) announced plans to initiate development of KP746, a recently identified oral prodrug of oxymorphone. Oxymorphone, marketed under the brand name Opana®, is a commonly prescribed medication for the management of pain in patients where an opioid anagelsic is appropriate. KP746 has the potential to be the first approved prodrug of oxymorphone.[/size][/font]
[/size]Based on preclinical studies of KP746, KemPharm believes that the prodrug may offer enhanced bioavailability at typical therapeutic doses and abuse-deterrent features in comparison to standard oxymorphone. Specifically, based on preclinical studies, KemPharm believes KP746 may be highly tamper-resistant and may be stable under conditions that can potentially defeat many other abuse-deterrent technologies, suggesting greatly reduced intranasal bioavailability and minimal to no release of oxymorphone when administered intravenously.[/color]
[/size]KP746 applies KemPharm’s Ligand Activated Therapy (LAT) platform technology, adding to its pipeline of opioid prodrug product candidates, which includes KP201/APAP and KP201/IR (prodrugs of hydrocodone with and without acetaminophen), KP511/ER (a prodrug of hydromorphone), and KP606/IR (a prodrug of oxycodone). In addition, KemPharm is developing KP415, a prodrug of methylphenidate with controlled release (CR) features, for managing ADHD.[/color]
[/size]Travis C. Mickle, Ph.D., President and CEO of KemPharm, stated, “We are very pleased to introduce KP746 to our advancing pipeline of opioid prodrug candidates as we seek to enhance our clinical-stage product portfolio while progressing KP201/APAP through regulatory review and potential commercialization. Oxymorphone is a commonly prescribed opioid analgesic, which, while effective at treating the symptoms of pain, has been found to have the potential for abuse and misuse similar to other opioids. Like our other opioid prodrug candidates, KP746 has features that may deter tampering and abuse on the molecular level, potentially limiting opioid exposure when misused either intranasally, intravenously, orally, or when subjected to various physical and chemical manipulation techniques commonly used by opioid abusers.”[/color]
[/size][/color]
[/size]http://www.streetinsider.com/Corporate+News/KemPharm+(KMPH)+to+Initiate+Development+of+Oxymorphone+Oral+Prodrug+KP746/11181219.html[/color]
friendly
0
funny
0
informative
0
agree
0
disagree
0
like
0
dislike
0
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions

Tags:
 

Related Topics

  Subject / Started by Replies Last post
16 Replies
7608 Views
Last post December 12, 2016, 09:43:21 PM
by dysmorphic
4 Replies
4065 Views
Last post August 27, 2018, 08:46:23 PM
by bignasty
6 Replies
4879 Views
Last post October 15, 2015, 10:49:26 PM
by Zoops
10 Replies
5100 Views
Last post November 14, 2015, 01:46:17 PM
by Daughter of Dionysus
1 Replies
2911 Views
Last post March 18, 2016, 09:31:09 PM
by Specter
6 Replies
4660 Views
Last post May 17, 2016, 11:46:42 AM
by Griffin
8 Replies
6410 Views
Last post August 02, 2017, 04:32:38 PM
by Chip
19 Replies
9799 Views
Last post December 27, 2017, 01:27:48 AM
by nurse_K
0 Replies
2102 Views
Last post May 02, 2018, 07:44:57 AM
by Chip
0 Replies
2179 Views
Last post May 29, 2018, 03:23:44 PM
by Chip


dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse





TERMS AND CONDITIONS

In no event will d&u or any person involved in creating, producing, or distributing site information be liable for any direct, indirect, incidental, punitive, special or consequential damages arising out of the use of or inability to use d&u. You agree to indemnify and hold harmless d&u, its domain founders, sponsors, maintainers, server administrators, volunteers and contributors from and against all liability, claims, damages, costs and expenses, including legal fees, that arise directly or indirectly from the use of any part of the d&u site.


TO USE THIS WEBSITE YOU MUST AGREE TO THE TERMS AND CONDITIONS ABOVE


Founded December 2014
SimplePortal 2.3.6 © 2008-2014, SimplePortal